secwatch.observer — SEC 8-K summary
======================================

Issuer:     Invivyd, Inc. (IVVD)
CIK:        0001832038
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0001193125-24-257993
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Invivyd Q3 2024 net product revenue $9.3M but net loss widens to $60.7M; cash $106.9M
--------------------------------------------------------------------------------

- PEMGARDA net product revenue $9.3M, up from $2.3M in Q2 2024; not at previously anticipated rates.
- Net loss $60.7M ($0.51 EPS) vs $39.4M ($0.36 EPS) in Q3 2023; R&D spending rose to $57.9M.
- Cash and equivalents $106.9M; year-end 2024 cash expected at least $65M, targeting near-term profitability.
- NEJM published Invivyd letter on PEMGARDA immunobridging pathway; Ho Lab letter with conflicting in vitro data published same day.
- VYD2311 Phase 1 dosing began August 2024; preliminary data readout expected late Q4 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1832038/000119312524257993/0001193125-24-257993-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1832038/000119312524257993/d894288d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-257993

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer